SequelSEC

RenovoRx, Inc. RNXT

Pharmaceutical Preparations · CIK 0001574094 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$909.00K
Fiscal year ended 2026-06-30
Operating income
-$3.35M
Fiscal year ended 2026-06-30
Free cash flow
-$2.94M
Fiscal year ended 2026-06-30

RenovoRx, Inc. (RNXT) reported revenue of $909.00K and net income of -$2.91M for the fiscal year ended 2026-06-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from RenovoRx, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

RenovoRx, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$909.00K$563.00K$238.00K$266.00K$422.00K$197.00KUnavailable
Cost of revenue$143.00K$84.00K$28.00K$53.00K$152.00K$94.00KUnavailable
Gross profit$766.00K$479.00K$210.00K$213.00K$270.00K$103.00KUnavailable
Operating income-$3.35M-$3.47M-$3.52M-$3.20M-$2.68M-$3.11MUnavailable
Net income-$2.91M-$3.52M-$2.94M-$2.91M-$2.90M-$2.42MUnavailable
Research & development$1.20M$1.23M$1.50M$1.68M$1.43M$1.64MUnavailable
Weighted-average diluted sharesshares 47.30Mshares 38.03MUnavailableshares 36.65Mshares 36.58Mshares 31.40MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$2.00K$0$0$0Unavailable
Diluted EPS$-0.06$-0.09Unavailable$-0.08$-0.08$-0.08Unavailable
Selling, general & administrative$2.92M$2.72M$2.23M$1.73M$1.52M$1.57MUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

RenovoRx, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Cash & equivalents$9.48M$12.36M$7.02M$10.04M$12.31M$14.58M$7.15M
Total assets$11.47M$13.96M$8.10M$11.21M$13.64M$16.01M$8.12M
Current assets$10.81M$13.72M$7.89M$10.98M$13.40M$15.74M$7.83M
Total liabilities$2.49M$2.70M$2.67M$3.13M$3.00M$2.86M$3.64M
Current liabilities$1.88M$1.92M$1.96M$1.88M$1.56M$1.74M$1.91M
Total equity incl. NCI$8.98M$11.26M$5.42M$8.08M$10.64M$13.16M$4.48M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$383.00K$379.00K$189.00K$272.00KUnavailableUnavailable$0
Accounts receivable$480.00K$280.00K$139.00K$169.00K$363.00K$242.00K$43.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$866.00K$1.12M$799.00K$869.00K$671.00K$967.00K$586.00K

Cash flow

RenovoRx, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating cash flow-$2.87M-$3.71M-$3.02M-$2.27M-$2.30M-$3.38MUnavailable
Capital expenditures$71.00K$0$0$0$0$2.00KUnavailable
Investing cash flow-$71.00K$0$0$0$0-$2.00KUnavailable
Financing cash flow$55.00K$9.05M$0$0$34.00K$10.81MUnavailable
Net change in cash-$2.88M$5.34M-$3.02M-$2.27M-$2.27M$7.43MUnavailable
Stock-based compensation$570.00K$317.00K$285.00K$349.00K$345.00K$288.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$1.00K$0$1.00M$1.00MUnavailableUnavailable

Derived

RenovoRx, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Free cash flow-$2.94M-$3.71M-$3.02M-$2.27M-$2.30M-$3.38MUnavailable
Gross margin84.3%85.1%88.2%80.1%64.0%52.3%Unavailable
Operating margin-368.4%-616.2%-1479.8%-1203.0%-634.6%-1578.7%Unavailable
FCF margin-323.2%-658.8%-1268.9%-853.4%-545.5%-1717.3%Unavailable
SBC / revenue62.7%56.3%119.7%131.2%81.8%146.2%Unavailable
Current ratio5.74x7.15x4.02x5.83x8.61x9.07x4.10x
Revenue YoY growth115.4%185.8%UnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-320.2%Unavailable-1235.7%-1094.7%-686.0%UnavailableUnavailable
R&D / revenue132.0%218.1%630.7%633.5%337.9%833.5%Unavailable
CapEx / revenue7.8%0.0%0.0%0.0%0.0%1.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RNXT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.